A medicine you get only every two months to reduce your risk of acquiring HIV could be an option in the future, but only if two clinical trials show that it is safe and effective.
This Week in HIV Research: New Maturation Inhibitor May Work Against Protease Inhibitor-Resistant HIV
This week, a study finds that a new maturation inhibitor in development, GSK3532795, shows activity against HIV that is resistant to protease inhibitors.
"Without early and consistent partnership with the community in our efforts to incrementally develop a cure for HIV we may never achieve what people with HIV most hope a cure will offer them."
A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...
An interview with Dan Barouch, M.D., Ph.D., on the key challenges in vaccine development, the pursuit of vaccines to potentially cure HIV and why we should be excited about antibodies.
"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.
Two cohort studies showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.
Scientists at The Scripps Research Institute (TSRI) have discovered a way of creating HIV- resistant cells by using antibodies to block HIV directly on the cell surface.
Combined with tenofovir alafenamide/emtricitabine (TAF/FTC, Descovy), the investigational HIV integrase inhibitor bictegravir matched the licensed integrase inhibitor dolutegravir (Tivicay, DTG) in viral suppression and safety, according to phase-2 s...
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.